Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
Bullboard Posts
User Avatar Image
(3)
•••
Comment by Zamboni99on Feb 01, 2018 11:00pm
137 Views
Post# 27486162

RE:New short format online video promo

RE:New short format online video promo
Advanced member
 
retiredcop - (2/1/2018 10:21:41 PM) 
New short format online video promo 
https://www.b-tv.com/promis-neuroscience-corporate-video/
Fairly slick, we-can-solve-this-thing-with-a-clever-little- ad mentality kind of clip. Will likely generate more interest and probably instill some trust in garden variety investors. I first heard of PMN on one of those little segments on BNN back in the spring. Seemed promising and I actually  bought in thinking I was watching the end of a feature interview with BNN. Didn’t reven realize it was just an ad segment until a few days later when there was a different company being promoted in the same spot! But no regrets obviously. It’s good to be in the money but I’d gladly trade it all for an AD treatment that worked. I believe a cure will come whether or not it’s PMN. I just wish it could have been a lot sooner for the sake of my mom.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities